Mkango Intersects Extensive Zones of Rare Earths

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
53
Mkango Intersects Extensive Zones of Rare Earths Mineralisation at the Songwe Hill Project in Malawi

LONDON and CALGARY, Alberta, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Mkango Resources Ltd. (AIM / TSXV: MKA) (the "Company" or "Mkango") is pleased to announce results for the first eight holes totaling 944 metres of its targeted 10,000 metre diamond drilling programme at the Songwe Hill Rare Earths Project (“Songwe”) in Malawi. The drilling programme is a key component of the ongoing Feasibility Study for Songwe. Highlights from the new results are as follows:

PX062 147.2 m 1 grading 1.6% Total Rare Earth Oxides (TREO) (5.3 – 152.5 m end of hole (EoH)). Inclined hole (70 degrees east).
PX065 91.0 m 2 grading 1.5% TREO (0.0 – 91.0 m) including 27.0 m 2 grading 2.0% TREO (23.0 – 50.0 m). Inclined hole (60 degrees west).
PX047 51.8 m grading 1.6% TREO (16.2 – 68.0 m). Inclined hole (60 degrees west).
PX046 48.0 m grading 1.2% TREO (4.0 – 52.0 m). Inclined hole (60 degrees south).
PX045b 9.2 m grading 2.0% TREO (6.1 – 15.3 m) and 27.5 m grading 1.5% TREO (30.5 – 58.0 m EoH). Vertical hole.
PX042 19.1 m grading 1.0% TREO (18.0 – 37.1 m). Inclined hole (60 degrees west).
PX036 42.8 m grading 1.3% TREO (87.3 – 130.1 m EoH) including 6.7 m grading 2.2% TREO (123.4 – 130.1 m EoH). Inclined hole (60 degrees west).

1 Includes a 2.0m cavity not sampled. 2 Includes a 2.7m cavity not sampled. TREO: total rare earth oxides based on total La 2 O 3 , Ce 2 O 3 , Pr 2 O 3 , Nd 2 O 3 , Sm 2 O 3 , Eu 2 O 3 , Gd 2 O 3 , Tb 2 O 3 , Dy 2 O 3 , Ho 2 O 3 , Er 2 O 3 , Tm 2 O 3 , Yb 2 O 3 , Lu 2 O 3 , Y 2 O 3 . These intersections are reported as down hole widths and do not necessarily represent true thicknesses and attitude of the mineralised zones, the estimation of which will require further refining of the geological model.

William Dawes, Chief Executive Officer, commented: “These are an excellent first set of results from the current programme and we look forward to announcing results from the remaining approximately 75 drill holes as they become available. The drill programme and planned resource update are fully funded following investments by Talaxis Limited totalling £6 million in January 2018. Talaxis will invest a further £7 million to fund completion of the Feasibility Study for Songwe on Mkango publishing a NI 43-101 technical report in relation to the resource update. ”

  • The drill programme is focused on infill drilling to confirm and upgrade the existing Indicated and Inferred Mineral Resource Estimates, testing extensions to the mineralisation and geotechnical drilling.
  • All eight drill holes intersected rare earth mineralisation, with the table above highlighting intersections averaging 1% TREO or more.
  • Drill holes PX065, PX062, PX046, PX047, PX042 and PX045b above were focused on infill drilling. Intersections of broad zones of mineralisation, as opposed to narrow veins or dykes, continue to support the concept of a bulk tonnage, open pit mining operation with low mining costs.
  • Drill hole PX036 was focused on testing the southerly extension of mineralisation. The significance of the more than 42 m of mineralisation intersected by PX036 at depth (87.3 – 130.1 m), including 6.7 metres grading 2.2% TREO to the end of the hole (130.1m), is being evaluated. This was the first hole in the project’s history to be drilled in the area near the summit of Songwe Hill. Another hole testing the southerly extension of mineralisation, PX037, did not reach the target depth.
  • A total of 8,466 metres of drilling, comprising 70 drill holes, has now been completed as at August 20, 2018.

A schematic geological map illustrating the location of the drill hole collars and estimated drill hole traces is available on the Company’s website ( www.mkango.ca ).

The breakdown of TREO values reported above are as follows:

                                           
  Drill Hole From To Interval   La 2 O 3 Ce 2 O 3 Pr 2 O 3 Nd 2 O 3 Sm 2 O 3 Eu 2 O 3 Gd 2 O 3 Tb 2 O 3 Dy 2 O 3 Ho 2 O 3 Er 2 O 3 Tm 2 O 3 Yb 2 O 3 Lu 2 O 3 Y 2 O 3 TREO
    m m m   ppm ppm ppm ppm ppm ppm ppm ppm ppm ppm ppm ppm ppm ppm ppm %
                                           
  PX062   5.3   152.5   147.2  (i)    4,226   7,157   736   2,524   364   96   225   27   113   18   43   5   30   4   512 1.6 %
                                           
  (i) Includes 2.0m cavity not sampled.                                  
                                           
                                           
  PX065 0.0   91.0   91.0  (i)    3,600   6,594   689   2,352   319   83   191   23   107   17   41   5   29   4   489 1.5 %
                                           
  including   23.0   50.0   27.0  (i)    5,595   9,574   954   3,020   370   91   196   21   88   13   27   3   16   2   329 2.0 %
                                           
  (i) Includes 2.7m cavity not sampled.                                  
                                           
                                           
  PX047   16.2   68.0   51.8     3,606   7,149   800   2,877   415   115   280   36   179   29   70   9   47   6   807 1.6 %
                                           
                                           
  PX046   4.0   52.0   48.0     2,486   5,129   577   2,104   317   92   227   30   146   25   60   8   47   6   703 1.2 %
                                           
                                           
  PX045b   6.1   15.3   9.2     5,257   8,278   806   2,752   469   136   330   44   224   42   118   18   112   14   1,318 2.0 %
      30.5   58.0   27.5     3,876   6,232   617   2,075   337   98   240   30   144   25   61   8   46   6   737 1.5 %
                                           
                                           
  PX042   18.0   37.1   19.1     2,490   4,263   440   1,496   235   70   174   23   112   18   41   5   31   4   486 1.0 %
                                           
                                           
  PX036   87.3   130.1   42.8     2,821   5,648   636   2,279   295   67   141   15   77   15   41   6   35   5   483 1.3 %
                                           
  including   123.4   130.1   6.7     5,540   10,403   1,078   3,582   391   83   162   15   65   11   29   4   28   4   357 2.2 %
                                           

Scientific and technical information contained in this release including sampling, analytical, and test data underlying the information has been approved and verified by Dr. Scott Swinden of Swinden Geoscience Consultants Ltd, who is a "Qualified Person" in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects.

Sample preparation and analytical work for the drilling and channel sampling programmes are being provided by Intertek-Genalysis Laboratories (Perth, Australia) employing ICP-MS techniques suitable for rare earth element (REE) analyses and following strict internal QAQC procedures inserting duplicates, blanks and standards. Internal Laboratory QAQC was also completed to include blanks, standards and duplicates.

About Mkango Resources Limited

Mkango's primary business is exploration for rare earth elements and associated minerals in the Republic of Malawi, a country whose hospitable people have earned it a reputation as “the warm heart of Africa”. The Company holds interests in three exclusive prospecting licenses in Malawi, the Phalombe licence, the Thambani licence and the Chimimbe Hill licence.

The main exploration target in the 80% held Phalombe licence is the Songwe Hill rare earths’ deposit, which features carbonatite-hosted rare earth mineralisation and was subject to previous exploration in the late 1980s. Mkango completed an updated Pre-Feasibility Study for the project in November 2015 and a Feasibility Study is currently underway, the initial phases of which include a major drilling programme.

Under the terms of an agreement with Talaxis, Talaxis will fully fund the Feasibility Study for Songwe by investing £12 million for a 49% interest in the project (via Mkango subsidiary Lancaster Exploration Ltd). Talaxis will also have the option to acquire a further 26% interest by arranging funding for project development including funding the equity component thereof. If Talaxis exercises its option, Mkango will retain a 25% interest, free carried to production. To-date, Talaxis has invested £5 million, which is funding the initial phase of the Feasibility Study, for a 20% interest in the project with Mkango holding 80%.

By investing a further £2 million, Talaxis will acquire a 49% interest in Maginito Ltd, a new subsidiary of Mkango focused on neodymium alloy powders, magnets and other technologies. This includes the collaboration with Metalysis Ltd announced in September 2017, which is focused on advanced alloys using neodymium or praseodymium with other elements for permanent magnet manufacturing. Permanent magnets are critical materials for most electric vehicles, direct drive wind turbines and many other high growth applications. Neodymium is a key rare earth component at Songwe. To date, Talaxis has invested £1 million for a 24.5% interest in Maginito with Mkango holding 75.5%.

The main exploration targets in Mkango’s remaining two 100% held licences are, in the Thambani licence, uranium, niobium, tantalum and zircon and, in the Chimimbe Hill licence, nickel and cobalt.

For more information, please visit www.mkango.ca .

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement may have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements (within the meaning of that term under applicable securities laws) with respect to Mkango, its business and the Project. Generally, forward looking statements can be identified by the use of words such as “plans”, “expects” or “is expected”, “scheduled”, “estimates” “intends”, “anticipates”, “believes”, or variations of such words and phrases, or statements that certain actions, events or results “can”, “may”, “could”, “would”, “should”, “might” or “will”, occur or be achieved, or the negative connotations thereof. Forward looking statements in this news release include statements with respect to the global market for products using the rare earth metals the Company is exploring for, completion of the feasibility study and of the transactions contemplated in the Agreement, as well as the use of proceeds from the investments into the Company by Talaxis and the timing of such expenditures. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. Such factors and risks include, without limiting the foregoing, market demand for the metals and associated downstream products for which Mkango is exploring, researching and developing, the positive results of a feasibility study on the Project, delays in obtaining financing or governmental or stock exchange approvals. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

For further information on Mkango, please contact: Mkango Resources Limited

William Dawes                                    Chief Executive Officer                  will@mkango.ca                                 UK: +44 207 3722 744 Canada: +1 403 444 5979 www.mkango.ca

Alexander Lemon President alex@mkango.ca @MkangoResources

Blytheweigh Financial Public Relations Tim Blythe, Camilla Horsfall, Julia Tilley UK: +44 207 138 3204

SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Jeff Keating, Caroline Rowe UK: +44 20 3470 0470

Alternative Resource Capital Joint Broker Alex Wood, Rob Collins UK: +44 20 7186 9004; +44 20 7186 9001

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 183

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 742

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 437

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 209

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 221

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Marina Genova Joins SEA Index to Promote Sustainable Yachting

Updated Category News Views 173

Marina Genova Enters SEA Index as an Institutional Member Recently, the Superyacht Eco Association – SEA Index welcomed Marina Genova, a prominent destination for yachting in the Mediterranean, as an Institutional Member. This collaboration signifies a crucial step in the yachting community's commitment to integrating environmental sustainability into its operations....

Continue Reading
Warren Buffett’s Top 2025 Stock Picks You Need to Know

Updated Category News Views 2610

Warren Buffett’s Strategic Stock Investments for 2025 Warren Buffett, the Oracle of Omaha, is known for his keen investment strategies and ability to recognize value in both good and bad market conditions. In the current volatile landscape, his portfolio continues to evolve, with some old favorites and new bets that show his forward-thinking approach. As we look ahead...

Continue Reading
Graves' Ophthalmopathy Market Surges with New Therapies

Updated Category News Views 50

Unexpected Growth in Graves' Ophthalmopathy Market Over the next decade, we're seeing the Graves' ophthalmopathy market gearing up for some serious growth, clocking in at a hefty compound annual growth rate of 9%. A good chunk of this is thanks to Viridian's newest player, LUMVOA, getting the green light, sending competitors scrambling and pushing innovation into...

Continue Reading
Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution

Updated Category News Views 210

So back in 2024, Tris Pharma rolled out ONYDA™ XR—this liquid medication aimed at tackling ADHD in kids six and older. It was billed as a game changer, especially since the FDA gave it the green light. The desks were buzzing about this first-of-its-kind non-stimulant therapy, positioning it like a golden ticket for parents tired of conventional stimulants that might...

Continue Reading
JPMorgan Updates Price Target for W. P. Carey to $70

Updated Category News Views 242

JPMorgan Boosts W. P. Carey's Price Target Recently, JPMorgan has refreshed its price target for W. P. Carey & Co. (NYSE: WPC), raising it from $68.00 to $70.00, while retaining an Overweight rating on the stock. This adjustment comes ahead of the company’s third-quarter earnings announcement, indicating the firm's confidence in W. P. Carey’s future potential....

Continue Reading